公司資料
Morphic Holding, Inc. 股價、新聞與催化劑
- 股票代碼:
- MORF
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for MORF.
公司概覽
業務概覽
Morphic was an integrin-focused biotechnology company with a pipeline in inflammatory and gastrointestinal disease before being acquired by Eli Lilly.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in specialty biotechnology.
商業模式特徵
The company was driven by novel biology, early clinical data, and the value of its integrin platform.
生技產業定位
Morphic was a targeted immunology name and now belongs to biotech M&A history.
未來催化劑
- Morphic is now mostly a closeout and acquisition story after the Lilly deal, so the catalysts are integration and any remaining corporate milestone. The market is not treating it like a live standalone pipeline name anymore.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。